Our Products
Cephalon offers a portfolio of innovative treatments for central nervous system disorders, pain, and cancer. We have eight proprietary products in the United States, and more than 30 products in 50 countries worldwide.
Click here to learn about our strong pipeline of innovative products in development.
NUVIGIL® (armodafinil) Tablets [C-IV] is the longer-lasting isomer of modafinil, the active ingredient in PROVIGIL®. NUVIGIL was approved by the U.S. Food and Drug Administration (FDA) to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy. In patients with OSA, NUVIGIL is used along with other medical treatments for this condition.
TREANDA® (bendamustine HCl) for Injection is a novel chemotherapeutic agent first approved for the treatment of chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow and the most common type of adult leukemia. TREANDA received its second approval for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. NHL is a serious and slow developing cancer of the lymphatic system that is difficult to treat because patients are prone to multiple relapses after therapy. While the exact mechanism of action is unknown, TREANDA may destroy cancer cells via several pathways, such as by damaging the DNA in cancer cells and by disrupting normal cell division. TREANDA is the first new agent approved by the FDA for the treatment of CLL since 2001, and the only new oncology medication to receive two indications in 2008.
AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is the first and only once-daily, extended-release skeletal muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. The medication is available in 15 and 30 mg dosage strengths. AMRIX is produced with Eurand Diffucaps® technology, which permits once-daily dosing.
FENTORA® (fentanyl buccal tablet) [C-II] is the first and only buccal tablet indicated for the management of breakthrough pain in opioid-tolerant patients with cancer, and the first tablet formulation of fentanyl approved for any use. Its proprietary OraVescent® drug delivery system was developed by the Cephalon drug delivery business in Minnesota.
TRISENOX® (arsenic trioxide) injection is a highly effective therapy for first and subsequent relapse in acute promyelocytic leukemia (APL). TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
The first and only FDA-approved SGRI, or selective GABA reuptake inhibitor, GABITRIL® (tiagabine hydrochloride) is indicated throughout much of the world as adjunct therapy for treatment of partial seizures associated with epilepsy.
PROVIGIL® (modafinil) Tablets [C-IV] was the first in a new class of wake-promoting agents, and the first FDA-approved prescription medicine for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder.
ACTIQ® (oral transmucosal fentanyl citrate) [C-II], a medicated lozenge on a handle, was the first prescription medication in the world approved for the treatment of breakthrough pain in opioid-tolerant cancer patients.
Authorized Distributors
Cephalon is committed to pedigree/compliance with state requirements for the sale and distribution of our pharmaceutical products.
Download List of Authorized Distributors of Record >>
Download CPSIA Compliance Letter >>